News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website


NeoPharm Investigators to Present Results of Cintredekin Besudotox Multicenter Phase I Clinical Studies at the World Federation of Neuro-Oncology Meeting


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www.pharmalive.com/News/index.cfm?articleid=234686&categoryid=40

Posted on: 04/30/2005

NeoPharm Investigators to Present Results of Cintredekin Besudotox Multicenter Phase I Clinical Studies at the World Federation of Neuro-Oncology Meeting



LAKE FOREST, Ill.--(BUSINESS WIRE)--Apr 29, 2005 - NeoPharm, Inc. (Nasdaq:NEOL) Why: Data results of multicenter Phase I studies of cintredekin besudotox in the treatment of recurrent high-grade glioma.

Where: Second Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO)
Edinburgh, Scotland

When: Friday, May 6, 2005 (all times Greenwich Mean Time +0, Edinburgh, Scotland)
Poster Display

-- 10:00 a.m. - 4:00 p.m. Medical & Surgical Therapies Section
-- Poster #114 "Peritumoral Convection-Enhanced Delivery of IL13-PE38QQR (IL13PE): Results of Multicenter Phase I Studies in Recurrent High Grade Glioma (HGG)"

Poster Presentation -- 1:00 p.m. - 2:30 p.m.
-- Presenter: Sandeep Kunwar, MD, Assistant Professor of Neurological Surgery and Principal Investigator in the Brain Tumor Research Center at the University of California-San Francisco
About NeoPharm, Inc.

NeoPharm, Inc., based in Lake Forest, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. The Company has a portfolio of cancer compounds in various stages of development. Additional information can be obtained by visiting NeoPharm's Website at: www.neophrm.com.

Forward Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company's drug development program, including, but not limited to clinical trials including cintredekin besudotox, and the Company's ongoing Phase I studies and PRECISE trial, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in financing, development, testing, obtaining regulatory approval, production and marketing of the Company's drug and non-drug compounds, including, but not limited to, cintredekin besudotox, uncertainty regarding the availability of third party production capacity, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug and non-drug compounds, including, but not limited to, cintredekin besudotox, that could slow or prevent products coming to market, uncertainty regarding the Company's ability to market its drug and non-drug products, including, but not limited to, cintredekin besudotox, directly or through independent distributors, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, cintredekin besudotox, and other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission including its annual reports on Form 10-K and quarterly reports on Forms 10-Q. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on these forward-looking statements as a prediction of actual future results. Contact NeoPharm, Inc. Paul Arndt, 847-295-8678 x 215 parndt@neophrm.com



Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740